The 5-HT 3 receptor antagonists (RAs) help maintain the standard of care, in various combinations with other agents, for prevention of chemotherapy-induced nausea and vomiting (CINV). Palonosetron is a new generation 5-HT 3 RA with indication not only acute but also delayed nausea and vomiting induced by moderately emetogenic chemotherapy (MEC). This study was carried out to determine the optimal dosage of palonosetron in combination with dexamethasone in patients in Japan.
introduction Chemotherapy-induced nausea and vomiting (CINV) are among the most common significant side-effects of cancer chemotherapy. CINV can become a major problem both for patients receiving highly emetogenic chemotherapy (HEC) and moderately emetogenic chemotherapy (MEC), especially in patients receiving a combination of anthracyclines and cyclophosphamide [1, 2] . Inadequate control of CINV can have a considerable negative impact on all aspects of patient quality of life and may lead patients to refuse to continue chemotherapy [1] . It is clear today that serotonin plays an important role in the development of CINV [3] . Control of acute nausea and vomiting improved significantly in the 1990s when 5-HT 3 receptor antagonists (RAs) were introduced into clinical practice. Combined with various agents, the 5-HT 3 RAs are now considered a standard of care [4] [5] [6] . The dose to be used varies in different settings. However, the effectiveness of original article *Correspondence to: Dr Y. Segawa, Department of Respiratory Disease, National Hospital Organization Yamaguchi-Ube Medical Center, 685 Higashi-Kiwa, Ube, Yamaguchi 755-0241, Japan. Tel: +81-836-58-2300; Fax: +81-836-58-5219; E-mail: ysegawa1174@aol.com previously developed 5-HT 3 RAs such as ondansetron, dolasetron, granisetron, and tropisetron, in preventing delayed nausea and vomiting (with symptoms occurring later than 24 h after chemotherapy) is considered less than optimal. In fact, patients still experience CINV when undergoing HEC or MEC even when multiple 5-HT 3 RAs are administered [7, 8] .
Palonosetron is a new highly potent and selective 5-HT 3 RA. It has a receptor binding affinity that is 100 times higher than previously developed 5-HT 3 RAs [9] and it has a significantly longer plasma elimination half-life, 40 h [10] compared with other agents in this class [11, 12] . Results from three phase III trials [13] [14] [15] and one phase II study, conducted in the Western patients [16] , indicated in a recommended dosage of 0.25 mg for palonosetron, administered as a single i.v. dose 30 min before chemotherapy. In the phase II study to determine the most appropriate dose of palonosetron (0.3-90 lg/kg) for patients receiving HEC, the two lowest effective doses were reported to be 3.0 and 10 lg/kg (reported to be equivalent to fixed doses of 0.25 and 0.75 mg per body, respectively) [16] . These two fixed doses of palonosetron were then compared with single i.v. doses of ondansetron 32 mg [15] and dolasetron 100 mg [14] in two phase III trials conducted in patients receiving MEC. In these trials, 0.25 mg of palonosetron was proven to control CINV with a clinically relevant better efficacy than ondansetron and dolasetron, at all times studied (acute, delayed, and overall phases). The difference in complete response (CR; no emesis and no rescue medication) rates between 0.25 mg palonosetron and comparator was around 15% in the delayed and overall phases. Both studies failed to show any advantage for patients who received 0.75 mg palonosetron. Of note, these studies included a minority of patients receiving corticosteroids. In contrast to the other 5-HT 3 RAs, palonosetron is given as a single injection to patients receiving MEC on the day of chemotherapy, to prevent CINV in the overall period following chemotherapy administration (1-5 days) [14, 15] . These data prompted the Food and Drug Administration (FDA) to grant palonosetron approval for the prevention of acute and delayed CINV in patients receiving MEC. Palonosetron is also approved for the prevention of CINV in European Union (EU) countries.
The current phase II, dose-ranging, randomized, doubleblind, multicenter study was conducted on patients receiving MEC in Japan to identify the most effective dose of palonosetron when combined with fixed doses of dexamethasone. The additional objective was safety assessment, in the evaluated dose range. Patients were stratified at randomization by gender and administration of paclitaxel (Taxol, BristolMyers K.K., Japan) using a minimization method. Dexamethasone 8 mg was also i.v. administered within 45 min before palonosetron administration. In case of MEC including paclitaxel, 20 mg dexamethasone, combined with 50 mg oral diphenhydramine and 20 mg i.v. famotidine or 50 mg i.v. ranitidine, was administered as premedication to prevent anaphylaxis at least 30 min before paclitaxel administration [19] . This study was approved by the Institutional Review Board at each participating institution and was conducted according to the Declaration of Helsinki. Written informed consent was obtained from each patient before they were enrolled in the trial.
efficacy parameters
The primary end point of this study was the proportion of patients who achieved a CR, defined as no emetic episode and no use of rescue medication during the first 24 h (acute phase) following administration of study chemotherapeutic agents. An emetic episode was defined as one episode of vomiting or a sequence of episodes in very close succession not relieved by a period of relaxation of at least 1 min, any number of unproductive emetic episodes (retching) in any given 5-min period, or an episode of retching lasting <5 min combined with vomiting not relieved by a period of relaxation of at least 1 min [15] . Secondary end points included CR rates from 24 to 120 h (delayed phase) and 0 to 120 h (overall phase); complete control (CC) rates, which was defined as no emetic episode, no need for rescue medication, and no more than mild nausea; time to treatment failure (first emetic episode or first need of rescue medication, whichever occurred first); number of emetic episodes; severity of nausea; and patient global satisfaction with antiemetic therapy as measured on a visual analogue scale.
study assessment procedures
Each consenting patient was screened for study eligibility within 7 days before being enrolled. Baseline assessment procedures included past medical history, vital sign measurements, concomitant medications, ECOG Annals of Oncology original article PS, physical examination, 12-lead ECG, and laboratory tests (complete blood count with differential, blood chemistry, urinalysis, and estimated creatinine clearance). All patients were required to be hospitalized at least until completing assessment on day 2. In addition, follow-up assessment was conducted on day 8 (permissible range days 6-10) and on day 15 (days [14] [15] [16] [17] [18] [19] [20] for each patient. Assessment procedures included vital sign measurements, physical examination, 12-lead ECG, and laboratory tests. Evaluation of daily emetic episodes, severity of nausea, and patient global satisfaction until day 5 were reported by the patient in a diary. Use of rescue medication was recorded on each patient's medical chart. Safety was assessed using CTCAE until day 15. All adverse events were reported, irrespective of study medications.
statistical analyses
In this dose-ranging study of palonosetron, CR rates in acute phase were assumed to be 67%, 85%, and 85% in the 0.075, 0.25, and 0.75 mg palonosetron dose groups, respectively. This assumption was based on the following: (i) the CR rate in acute phase was reported to plateau at a palonosetron dose ‡0.25 mg in two earlier phase III studies of MEC in Western patients [14, 15] ; (ii) concurrent use of dexamethasone (8 or 20 mg) in all patients in the present study would contribute a 10%-20% increase of CR rates [20] ; and (iii) the CR rate in the lowest dose of 0.075 mg was estimated to be 40% higher than the CR rate in the lowest dose group (24% in the 0.3 lg/kg dose group) of the preceding phase II study of HEC in Western patients [16] because the present study enrolled patients receiving MEC and all patients were administered dexamethasone with palonosetron. For the Cochran-Armitage trend test (contrast coefficient score setting: 22 at the 0.075 mg and 1 at the 0.25 and 0.75 mg dose groups), a sample size of 189 assessable patients was required to ensure a one-sided a level of 2.5% with a statistical power of 80%. Assuming five dropout patients per dose group, 204 patients were needed in this study. Statistical analyses were carried out using SAS software version 8.0 (SAS Institute, Inc., Cary, NC). The Cochran-Armitage trend test was used to determine the significance of differences in dose-response parameters (i.e. CR or CC rates) between dose groups. The v 2 test or Fisher's exact probability test was used to compare proportions of categorical variables. The difference in mean values of baseline characteristics was tested using one-way analysis of variance. The number of emetic episodes, severity of nausea, and patient global satisfaction were compared between dose groups using the Kruskal-Wallis test. Time-to-event distributions were calculated using the method of Kaplan and Meier, and differences between these distributions were assessed using the log-rank test. Analyses of efficacy end points were carried out for the full analysis set (FAS) population, which was defined as those of patients receiving both palonosetron and level 3 or 4 emetogenic chemotherapy agents on day 1. Furthermore, additional efficacy analyses were carried out for the subgroup patients receiving combination chemotherapy of AC/EC, which is considered to be more emetogenic than MEC agents. Safety data for all patients receiving palonosetron were tabulated and summarized descriptively.
results

patient baseline demographics
We enrolled 211 patients in this study from 19 institutions. Patients were randomly assigned to one of the three palonosetron dose groups. Efficacy and safety analyses were carried out for the FAS population (67, 68, and 69 patients, respectively, in the 0.075, 0.25, and 0.75 mg palonosetron dose groups) because seven patients who had never received palonosetron were excluded (three patients each in the 0.075
Baseline demographic data and characteristics of patients in the FAS cohort are presented in Table 1 . There were no differences between the groups in the distribution of patients by gender, age, height, weight, or ECOG PS. The most common types of tumor cancer were non-small-cell lung cancer (n = 108) followed by breast cancer (n = 82) and small-cell lung cancer (n = 9). The most common chemotherapeutic agents administered on day 1 were carboplatin (n = 112), paclitaxel (n = 96), cyclophosphamide (n = 83), epirubicin (n = 45), and doxorubicin (n = 36). Eighty patients received a combination of anthracyclines and cyclophosphamide (AC/ EC). There were no differences in the proportion of cancer types or chemotherapy agents administered in individual palonosetron dose groups. Figure 1A ). There was no significant dose-response relationship found with the Cochran-Armitage trend test (contrast coefficients: 22 at the 0.075 mg and 1 at the 0.25 mg and 0.75 mg dose groups; P = 0.2499), where age (<65 or ‡65 years) and gender were included as stratification factors because they were identified as covariates on blind review.
secondary efficacy analysis
For the delayed (24-120 h) and overall (0-120 h) periods, the CR rates increased in a dose-dependent way, although not with clinical relevance (62.7%, 66.2%, and 71.0% for the delayed and 59.7%, 64.7%, and 69.6% for the overall period in the 0.075, 0.25, and 0.75 mg palonosetron dose groups, respectively; Figure 1A ), and a similar increase was observed in CR rate among the three dose groups for the cumulative periods (Table 2) as well as successive 24-h periods (24-48, 48-72, 72-96, and 96-120 h; data not shown). The CC rates for the acute, delayed, and overall periods were similar to those in the CR evaluation (data not shown). In addition, the number of emetic episodes, severity of nausea as assessed by the four-point Likert scale, and patient global satisfaction did not differ among the three palonosetron dose groups (data not shown). Cumulative CR rates in patients who received a combination of anthracyclines (doxorubicin or epirubicin) and cyclophosphamide (AC/EC, n = 80) are shown in Figure 1B and Table 2 . In this subgroup of patients who received less corticosteroids, a dose-dependent increase in CR rates was observed, with increases of >10%, showing better efficacy in the 0.75 mg dose group. These differences did not reach statistical significance. CR rates in patients receiving agents other than the AC/EC regimen, mainly carboplatin and paclitaxel, were 95.1%-100.0% in the acute phase and 76.2%-78.0% in the delayed phase ( Figure 1C) .
The time to treatment failure in the FAS population and AC/ EC subgroup are shown in Figure 2A and B (n = 203 and n = 80, respectively). One patient in the 0.25 mg palonosetron dose group discontinued the study and was excluded from the FAS for this analysis. The median time to treatment failure in the FAS population was >120 h in all three dose groups, with first quartile times of 41.8, 44.3, and 72.2 h, respectively, in the 0.075, 0.25, and 0.75 mg palonosetron dose groups. In the AC/ EC subgroup analysis, the median time to treatment failure was 36.2, 55.8, and >120 h, respectively, in the 0.075, 0.25, and 0.75 mg palonosetron dose groups. However, these differences did not reach statistical significance.
safety evaluation
Of the total 204 patients evaluated for safety, 67 (100%), 67 (98.5%), and 69 (100%) experienced at least one adverse event, in the 0.075, 0.25, and 0.75 mg palonosetron dose groups, respectively. Adverse drug reactions appeared in 22 (32.8%), 17 (25.0%), and 16 (23.2%) patients in the 0.075, 0.25, and 0.75 mg palonosetron dose groups, respectively. In addition, serious adverse events were reported in 10 (4.9%) patients, all of which were assessed as not related to palonosetron. A list of 
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common treatment-related adverse events is given in Table 3 .
The most common adverse events related to palonosetron were constipation (n = 20) and headache (n = 9). Neither the incidence nor the severity of these events was dependent on dose. In this study, safety assessments were similar to what was reported in the safety profile observed in previous phase III trials [13] [14] [15] conducted in Western patients.
discussion
Palonosetron has been approved for CINV induced by MEC both in United States and EU at 0.25 mg i.v. Its peculiar characteristics are high affinity for the receptor and prolonged duration of action. The FDA approved palonosetron for both acute and delayed emesis (i.e. up to 120 h of observation). The present dose-ranging study was conducted in patients receiving MEC in Japan. At the time this study was planned, the AC/EC regimens were considered MEC. Eighty of 204 patients (39.2%) received such regimens.
A slight but not clinically relevant dose-response relationship for antiemetic efficacy was observed in the FAS patient population between the three tested doses in the acute, delayed, and overall phases. Interestingly, in the subgroup of patients receiving AC/EC, the CR rates for the delayed and overall phases appeared to increase with dose and showed the highest efficacy in the 0.75 mg dose group. The lowest dose appeared to be suboptimal in the delayed (CR = 38.5%) and overall (CR = 30.8%) periods. The 0.75 mg dose appeared to be at least 20% more efficacious in the acute phase (CR = 85.2%) in comparison to 0.075 mg (CR = 61.5%) and 0.25 mg (CR = 63.0%). In the delayed period, it was 15% better than the dose of 0.25 mg (CR, respectively, of 63.0% and 48.1%), while in the overall phase, CR accounted, respectively, for 59.3% and 44.4%, showing another difference of 15%. The difference of 15% between the two doses shows numerically higher CR rates for the 0.75 mg dose with overall safety similar to other dose groups and shows the same clinical difference found between palonosetron and comparators in the pivotal clinical phase III studies conducted in Europe and the United States, that included regimens of cyclophosphamide and/or anthracyclines [14, 15] . The highest dose level was shown to better protect from CINV those patients who received a regimen of AC/EC. On the other hand, CR rates in the patients receiving agents other than AC/EC showed no original article Annals of Oncology significant difference among the three dose groups in the acute, delayed, and overall periods. This subgroup population included mainly patients receiving paclitaxel combined with carboplatin and they were given high-dose dexamethasone (20 mg), diphenhydramine, and histamine H 2 -RA (famotidine or ranitidine) as premedication to prevent anaphylaxis. The CR rates in this subgroup were most likely influenced by the concomitant use of dexamethasone and diphenhydramine, which are also listed as antiemetic agents in the guidelines [21, 22] . This may also possibly have resulted in the absence of dose response through the efficacy evaluation period in this subgroup population.
Palonosetron was well tolerated in all the dose groups. Incidences, frequencies, intensities, and drug relationships of AEs appeared to be equally distributed among the three dose groups with no apparent relationship to dose. In another Japanese phase II study, conducted in patients receiving HEC, no differences were apparent in protection from CINV for 0.25 and 0.75 mg doses. Also in this trial, no differences in safety profile were evident between the two dose groups [23] .
In conclusion, the trends for better efficacy and the excellent safety profile of palonosetron in this trial and the phase II HEC trial indicate that 0.75 mg could be the recommended dose of palonosetron for future studies in the Japanese population. 
